Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

IGC Pharma (IGC) Gross Profit (2016 - 2025)

IGC Pharma has reported Gross Profit over the past 16 years, most recently at $99000.0 for Q3 2025.

  • Quarterly Gross Profit fell 50.0% to $99000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $511000.0 through Sep 2025, down 23.16% year-over-year, with the annual reading at $619000.0 for FY2025, 15.55% down from the prior year.
  • Gross Profit was $99000.0 for Q3 2025 at IGC Pharma, down from $154000.0 in the prior quarter.
  • Over five years, Gross Profit peaked at $255000.0 in Q2 2023 and troughed at $26000.0 in Q2 2021.
  • The 5-year median for Gross Profit is $133000.0 (2023), against an average of $119368.4.
  • Year-over-year, Gross Profit surged 446.15% in 2022 and then crashed 50.0% in 2025.
  • A 5-year view of Gross Profit shows it stood at $62000.0 in 2021, then soared by 64.52% to $102000.0 in 2022, then skyrocketed by 30.39% to $133000.0 in 2023, then decreased by 21.8% to $104000.0 in 2024, then fell by 4.81% to $99000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Gross Profit are $99000.0 (Q3 2025), $154000.0 (Q2 2025), and $154000.0 (Q1 2025).